DiCE Molecules Overview
- Founded
- 2013
- Status
- Public
- Employees
- 40
- Stock Symbol
- DICE
- Share Price
- $16.24
- (As of Monday Closing)
DiCE Molecules General Information
Description
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Contact Information
Website
www.dicetherapeutics.com
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Stock Exchange
NAS
Primary Office
- 279 East Grand Avenue
- Suite 300, Lobby B
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
DiCE Molecules Timeline
DiCE Molecules Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.24 | $16.19 | $13.39 - $40.50 | $619M | 38.2M | 327K | -$8.42 |
DiCE Molecules Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|
| EV | 1,258,294 | ||
| Revenue | 1,313 | 863 | 5,775 |
| EBITDA | (39,149) | (23,168) | (12,841) |
| Net Income | (39,894) | (23,739) | (12,938) |
| Total Assets | 342,382 | 63,861 | 31,181 |
| Total Debt | 2,367 | 98 | 222 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
DiCE Molecules Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore DiCE Molecules‘s full profile, request access.
Request a free trialDiCE Molecules Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore DiCE Molecules‘s full profile, request access.
Request a free trialDiCE Molecules Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of n
Drug Discovery
South San Francisco, CA
40
As of 2021
00000
0000
0000-00-00
00000000
00000
00000000
m veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
0000 000000000
Middleton, WI
00
As of 0000
000.00
0000000000 0
000.00
00000 00
a. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 00000000
South San Francisco, CA
000
As of 0000
00000
000000 - 000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialDiCE Molecules Competitors (93)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Middleton, WI | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000 000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Boston, MA | 00 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Venture Capital-Backed | Ghent, Belgium | 00 | 00000 | 00000000000 | 00000 |
| 000000 | Venture Capital-Backed | Pomona, CA | 0 | 00000 | 0000000000 0 | 00000 |
DiCE Molecules Patents
DiCE Molecules Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170348666-A1 | Methods of routing, compositions and uses thereof | Abandoned | 05-Jun-2016 | 00000000000 | |
| EP-3464590-A1 | Methods of routing, compositions and uses thereof | Withdrawn | 05-Jun-2016 | 00000000000 | |
| EP-3464590-A4 | Methods of routing, compositions and uses thereof | Withdrawn | 05-Jun-2016 | 00000000000 | 0 |
| JP-2019523646-A | Route determination methods, compositions, and uses thereof | Pending | 05-Jun-2016 | 00000000000 | |
| EP-3359640-A4 | Methods of estimating logd of tagged combinatorial library compounds | Withdrawn | 09-Oct-2015 | G01N33/92 | 0 |
DiCE Molecules Executive Team (7)
DiCE Molecules Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Geeta Vemuri Ph.D | Agent Capital | Board Observer | 000 0000 |
| J. Judice Ph.D | DiCE Molecules | Chief Executive Officer & Board Member | 000 0000 |
| Jake Simson Ph.D | Self | Board Member | 000 0000 |
| James Scopa JD | Self | Board Member | 000 0000 |
| John Bedbrook Ph.D | DiCE Molecules | Co-Founder & Board Member | 000 0000 |
DiCE Molecules Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialDiCE Molecules Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore DiCE Molecules‘s full profile, request access.
Request a free trial